Related Experiment Video

Updated: Aug 16, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

The use of memantine in dementia with Lewy bodies

Marwan N Sabbagh1, Ann Marie Hake, Sahir Ahmed

  • 1The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA. Marwan.sabbagh@sunhealth.org

Journal of Alzheimer'S Disease : JAD
|September 1, 2005
PubMed
Abstract

Insights

Memantine shows variable effects in Dementia with Lewy Bodies (DLB) patients, with some improving and others worsening. The drug appears safe for DLB treatment, though outcomes differ.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Memantine is effective for Alzheimer's disease and other dementias.
  • Limited data exists on memantine's efficacy in Dementia with Lewy Bodies (DLB).

Purpose of the Study:

  • To evaluate the effects of memantine in patients diagnosed with Dementia with Lewy Bodies (DLB).

Main Methods:

  • Retrospective chart review of 11 DLB patients meeting McKeith Criteria.
  • Patients were treated with memantine, with or without cholinesterase inhibitors (ChEIs).

Main Results:

  • Seven out of eleven DLB patients showed stable or improved symptoms with memantine.
  • Four patients experienced worsening symptoms or adverse reactions to memantine.
  • No negative impact on motor function was observed.

Conclusions:

  • Memantine can be safely administered to patients with DLB.
  • The symptomatic response to memantine in DLB is inconsistent.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...